The Year in Intracoronary Imaging  by Muller, James E. et al.
TT
J
B
T
o
g
t
t
i
a
a
p
i
a
r
a
i
u
u
s
m
d
(
p
g
t
p
I
t
A
s
o
F
a
F
S
M
J A C C : C A R D I O V A S C U L A R I M A G I N G V O L . 3 , N O . 8 , 2 0 1 0
© 2 0 1 0 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 1 9 3 6 - 8 7 8 X / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . D O I : 1 0 . 1 0 1 6 / j . j c m g . 2 0 1 0 . 0 5 . 0 1 0H E Y E A R I N I M A G I N G
he Year in Intracoronary Imaging
ames E. Muller, MD,* Neil J. Weissman, MD,† E. Murat Tuzcu, MD‡
urlington, Massachusetts; Washington, DC; and Cleveland, Ohiot
p
i
b
I
i
i
m
p
3
I
A
a
p
(
f
t
I
m
t
d
t
e
d
d
t
a
t
a
s
m
lth R
men
c. Dhe past year was one of rapid development
f novel intracoronary imaging methods with
reat potential to improve the care of pa-
ients. The impetus for the development of
hese new imaging methods has been a grow-
ng recognition of the limitations of coronary
ngiography—the dominant method for the
ssessment of coronary artery disease for the
ast 50 years. Examples of the remarkable
mages that can now be obtained in patients
re shown in Figure 1 (1–3).
In most cases, the imaging techniques inter-
ogate the coronary wall using either optical or
coustic signals delivered and retrieved by an
ntracoronary catheter. Although intravascular
ltrasound (IVUS) and angioscopy have been
sed for decades, many of the methods under
tudy are new, including optical approaches
ade possible by advanced lasers and optical
etectors developed for use with the Internet
Table 1).
These new intracoronary imaging methods
rovide information often unobtainable by an-
iography that may improve treatment of both
he culprit lesion and the nonculprit vulnerable
laques responsible for subsequent events (4).
ntracoronary Imaging to Improve Outcomes at
he Culprit Lesion Site
lthough the safety of coronary stenting has
teadily improved the procedural complications
f no or slow-reflow and peri-stenting infarc-
rom *InfraReDx, Inc., Burlington, Massachusetts; †MedStar Hea
nd Georgetown University, Washington, DC; and the ‡Depart
oundation, Cleveland, Ohio. Dr. Muller is CEO of InfraReDx, In
cientific.anuscript received January 20, 2010; revised manuscript received Apion continue to occur in approximately 10% of
atients. Within a year, restenosis is observed
n 5% to 10% of patients, whereas stent throm-
osis occurs in approximately 1% by 2 years.
ntracoronary imaging may prove to be useful
n reducing these complications by 1) improv-
ng the techniques of stent sizing and place-
ent, 2) identifying the role of necrotic-core
laque as a cause of stent complications, and
) assessing stent coverage and thrombosis.
maging to ImproveStent SizingandPlacement
lthough angiographic guidance alone gener-
lly produces excellent outcomes, it has been
roposed that the occasional complications
dissection, stent thrombosis, restenosis) result
rom a mismatch of vessel and stent size, failure
o end the stent in an area of less plaque by
VUS, or failure to expand the stent leading to
alapposition. Recently, Roy et al. (5) reported
hat IVUS guidance was an independent pre-
ictor of freedom from stent thrombosis, al-
hough there was no reduction in overall
vents. Doi et al. (6) demonstrated that re-
uced stent area determined by IVUS imme-
iately after stenting is an independent predic-
or of subsequent in-stent restenosis. Gerber et
l. (7) reported that IVUS-guided stent dila-
ion led to larger lumen areas than did
ngiography-guided stenting. A randomized
tudy of the value of IVUS guidance to opti-
ize stenting has been initiated.
esearch Institute at Washington Hospital Center
t of Cardiovascular Medicine, Cleveland Clinic
r. Weissman receives grant support from Bostonril 26, 2010, accepted May 13, 2010.
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882ecroticCorePlaqueasaCauseof StentingComplications
ecrotic-core plaque and peri-stenting myocardial
nfarction (MI). Perhaps the greatest recent contri-
ution of intracoronary imaging to understanding
tenting complications has been the confirmation
hat balloon dilation of stenoses with necrotic
ores produces emboli leading to peri-stenting
I. This phenomenon has been documented
ith the use of angioscopy (8), gray-scale IVUS
9), virtual histology (VH) IVUS (10), integrated
ackscatter (IB) IVUS (11), optical coherence
omography (OCT) (12) and near-infrared (NIR)
pectroscopy (3).
Dilation of the necrotic core may also cause
laque shift that might in turn lead to side branch
cclusion. Wei et al. (13) reported that balloon
nflation led to a reduction in necrotic core (assessed
by VH-IVUS), and a shift of plaque away
from the ballooned area.
Intracoronary ImagingandLate
Stent Thrombosis
Failure of endothelial coverage of stent
struts is a cause of thrombus and may occur
more frequently when stents are placed
over a necrotic core (14–16). OCT studies
show that the incidence of malapposed
struts is higher with sirolimus-eluting
stents (SES) than with bare metal stents
(BMS) (17,18). Tanigawa et al. (19) found
that use of an SES was a predictor of
malapposition, as were overlap stenting,
post-dilation type C lesions, diabetes mel-
litus, and inflation pressure (Fig. 2).
Murakami et al. (20) found a greater
incidence of in-stent thrombus in paclitaxel-
oated stents compared with SES. An OCT
ollow-up study demonstrated that uncovered
truts persist up to 2 years after SES implanta-
ion, suggesting the need for further follow-up
21). Hassan et al. (22) found that the risk of
cquired stent malapposition detected by IVUS
as 4-fold higher with DES than BMS and the
isk of very late stent thrombosis was higher in
hose with late malapposition. Takano et al. (23)
bserved a very high incidence of mural thrombus
s detected by angioscopy 6 months after DES
mplantation despite angioscopic evidence of
tent coverage by neointima. The discordance
etween frequent mural thrombus and infrequent
linical stent thrombosis is presumably due to
ss
und
iac
y
t
mantiplatelet therapy (Fig. 3). sFinn et al. (14) suggested that BMS, because they
ndothelialize more readily than DES, may be pre-
erred for a necrotic-core plaque when other factors
avoring a BMS or a DES are equally balanced. These
onclusions were based on autopsy findings not pre-
eded by in vivo imaging. There is extensive clinical
rial evidence supporting the safety of DES in acute
oronary syndrome cases in which necrotic cores are
ikely to have been stented (24).
Abbott (25) noted that although both OCT and
ngioscopy can provide information about the pres-
nce of tissue over a stent, the tissue observed is not
lways thrombo-resistant endothelium. Higo et al.
26) found by angioscopy that neointima within an
ES became increasingly yellow by 10 months and
as associated with mural thrombus, whereas neo-
ntima within a BMS was more likely to be white
nd not associated with thrombus. Murakami et al.
27) also reported that neointima within an SES
as yellow on angioscopy and showed OCT signs
f a lipid-core plaque that were not observed in
eointima over a BMS. Nakazawa et al. (28) noted
hat the angioscopic findings of yellow after SES
lacement and pathologic observations suggest that
ertain stents might create a “nouveau atheroscle-
osis” with unfavorable long-term consequences.
Intracoronary imaging, although not currently
apable of detecting endothelial cells or measuring
heir function, is likely to play an important role in
esolving the problem of late stent thrombosis
ecause of its ability to identify thrombus and stent
overage. The intracoronary imaging findings that
truts are often uncovered, that mural thrombus is
requent, and that even visible neointima may not
e functional have implications for the duration of
ntiplatelet therapy and indicate the need for im-
roved stent technology. It seems that the stent
hrombosis rate may be lower with newer stents
esigned with less metal (leading to improved
ndothelialization) (29). Bioabsorable stents re-
ove the problem of the prolonged presence of a
hrombogenic substance requiring development of
ew thrombo-resistant endothelium (30,31). The
ew methods of intracoronary imaging may be
seful in the evaluation of new types of stents
esigned to improve endothelial coverage and de-
rease stent thrombosis.
dentification of Vulnerable Plaque at
onculprit Sites
lthough detection of vulnerable plaque—the pre-B B R E V I A T I O N S
N D A C R O N YM S
MS bare metal stent
SS endothelial shear stre
B integrated backscatter
VUS intravascular ultraso
ACEmajor adverse card
vent
Imyocardial infarction
IR near-infrared
CT optical coherence
omography
CI percutaneous coronar
ntervention
ES sirolimus-eluting sten
CFA thin cap fibroatheroumed cause of a subsequent coronary event from a
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883onculprit lesion—is a major goal of intracoronary
maging, the term has been used with 4 different
eanings (Table 2). The original definition de-
cribed a concept (a plaque prone to disruption
nd thrombosis) (32), whereas angiographic
tudies indicated that such plaques are not nec-
ssarily stenotic at baseline (33,34). Autopsy data
ndicated that an inflamed thin cap fibroatheroma
TCFA) is likely to be a vulnerable plaque. The
ecent PROSPECT (Predictors of Response to
ardiac Resynchronization Therapy) study (37)
sed a broader definition that includes plaques
ikely to cause progressive angina. It could include a
laque not stented at the initial percutaneous cor-
nary intervention (PCI) that caused angina with or
ithout a minor nonthrombotic increase in stenosis
uring follow-up.
In September 2009, the results of the PROSPECT
tudy, the first prospective, large-scale, long-term
ttempt to identify vulnerable plaques, were re-
orted at the Transcatheter Cardiovascular Thera-
eutics (TCT) annual meeting (37). The study was
onducted in 700 patients receiving PCI for an
cute coronary syndrome. The PROSPECT study
sed the new, broad definition of a vulnerable plaque
s a plaque, not the original culprit at the index event,
ikely to cause a major adverse cardiac event (MACE)
fter PCI. MACE was defined as cardiac death,
ardiac arrest, MI, unstable angina, or increasing
ngina requiring revascularization or rehospitalization.
The primary findings were as follows: 1) by 3.4
ears, 20.4% of the patients experienced a second
vent, only 4.9% of which were “hard” (cardiac
eath, cardiac arrest, and MI), leaving 15.5% with
rogressive angina or unstable angina (Fig. 4).
) Approximately half of the events occurred at the
revious culprit lesion site and half at sites not
reated at the initial PCI. 3) Sites with a plaque
urden of 70% as shown by IVUS, a VH-TCFA,
nd lumen area 4 mm2 had a 17% risk of causing
n event versus a risk of 2% for plaques without
hose 3 features (37).
These results are provocative. Although the rates
f cardiac death and MI were lower than expected
presumably due to medical therapy including anti-
hrombotic agents), the PROSPECT study dem-
nstrated the ability of imaging to identify non-
tented sites likely to cause MACEs after stenting
f a culprit lesion. The PROSPECT study did not
dentify novel features of plaques prone to disrup-
ion and thrombosis—the original definition of
ulnerable plaque—for 2 reasons. First, the broad
efinition of vulnerable plaque used—a plaque nikely to cause an MACE event after stenting—
ncluded increasing angina that may not have been
ue to plaque disruption and thrombosis. Second,
he successful predictors that included the finding
f a lumen area 4 mm2 provide relatively little
ew information because such narrowing is gener-
lly considered a sign of a flow-limiting stenosis in
Figure 1. Novel Intracoronary Imaging Devices
(A) A ﬂy-through view obtained by optical Fourier domain imaging
a stent implanted 9 years earlier and a new stent (B) (1). (C and D)
sectional view showing struts of the 2 stents. (E) Angiogram showin
stenosis at a site of a thin-cap ﬁbroatheroma (TCFA) by both virtua
ogy (center) and optical coherence tomography (OCT) (right) (2).
(F) Six months later, rupture of the TCFA, documented by OCT, led
ble angina. (G) Near-infrared spectroscopic data showing a circumfe
lipid-core plaque at a stenosis; balloon dilation led to severe no-reﬂ
sumably due to embolization of plaque contents (3).showing
Cross-
g a 50%
l histol-
to unsta-
rential
ow, pre-eed of treatment regardless of future vulnerability.
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884ull interpretation of the PROSPECT study will
ot be possible until multiple publications are avail-
ble describing the results of this extensive trial. For
he present, the PROSPECT study investigators
tated that the positive results of the trial did not
upport the routine performance of 3-vessel IVUS
o identify vulnerable plaques.
hear Stress to Identify SitesVulnerable to
ecomingVulnerable
he plaques suspected to be vulnerable are not
andomly distributed throughout the coronary tree.
s would be expected from extensive vascular biol-
gy research showing the atherogenic effects of low
ndothelial shear stress (ESS), Chatzizisis et al. (38)
ound in swine that low ESS detected in vivo after
3 weeks of an atherogenic diet predicted the
evelopment by 30 weeks of lipid-laden high-risk
laques. Sites with low ESS also showed enhanced
ctivity of matrix-degrading proteases—enzymes
mplicated in formation of plaques with necrotic
ores (39). Conversely, Gijsen et al. (40) found that
aximum plaque deformability was found at sites
xposed to the highest ESS (40). The varied findings
emonstrate the complex interactions among ESS,
he stage of development of the plaque, expansive
emodeling, and the development of stenosis.
Figure 2. Strut Apposition as Determined by OCT
y Imaging Techniques
eveloped and Used in Patients
Within the Past Decade In Development
H-IVUS Raman spectroscopy
-IVUS Time resolved laser-induced
ﬂuorescence spectroscopy
CT Fluorescence angioscopy
FDI-OCT Molecular imaging
ear-infrared spectroscopy
er; IVUS  intravascular ultrasound; OCT  optical coherence tomography;
omain imaging; VH  virtual histology.Arrows indicate stent struts. Reprinted, with permission, from Tanigawadentificationof TCFAs
bundant pathologic and clinical data (36) indicate
hat TCFAs, which have many features attractive
or imaging (Table 3), are likely to be vulnerable
laques. Different intracoronary imaging methods
ave different strengths and weaknesses for detect-
ng the various features of interest. We focus mainly
n those technologies capable of detection of the
ecrotic core, the largest feature of TCFA and
erhaps the most attractive target for imaging.
etectionof theNecrotic Core
VUS-based methods. IVUS, which is in widespread
se to identify plaque structure and stent features,
an also be used for plaque characterization. The 4
VUS-based methods that have been used to iden-
ify necrotic core—gray-scale IVUS, VH-IVUS,
B-IVUS, and palpography—were reviewed re-
ently (41).
Lee et al. (42) reported that attenuated plaque,
efined as hypoechoic plaque not due to calcium
hadowing and considered to represent necrotic
ore by gray-scale IVUS, was never found in stable
atients, but was observed in 39.9% of patients with
T-segment elevation MI, supporting the associa-
ion of attenuated plaque with necrotic-core plaque
nd/or a platelet thrombus. In contrast, Bayturan et
l. (43) found that attenuated plaques were found
ith equal frequency in stable and unstable patients
nd not associated with subsequent coronary events.
As noted previously, patients with attenuated
laque were also more likely to experience a cardiac
nzyme elevation after PCI, suggesting the presence
f a necrotic core at the dilated site.
The limitations of gray-scale IVUS for tissue
haracterization led to the development of VH-
VUS and IB-IVUS, which use information in the
adiofrequency backscattered IVUS signal not dis-
layed on the gray-scale screen.Table 1. Intracoronar
Used in Patients
for >2 Decades
D
Angioscopy V
Gray-scale IVUS IB
O
O
N
IB  integrated backscattet al. (19). Abbreviation as in Figure 1.
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885A VH-TCFA has been defined as a plaque that
n 3 adjacent cross sections has a plaque burden
40% and a confluent necrotic core occupying
10% of the cross section of the artery that is in
ontact with the lumen (37). In studies of groups of
atients, this definition has led to identification of
laques showing the expected features of necrotic
ores. VH-TCFAs have been found to be more
requent in lesions causing acute coronary syn-
romes (44) and lesions causing embolization-
elated peri-stenting infarction (10). Similar studies
re available for IB-IVUS. Okubo et al. (45) reported
hat IB-IVUS performed better than VH-IVUS in a
orrelation with a histologic gold standard.
The presence of a VH-TCFA is currently being
sed to select the plaques randomly assigned to
Figure 3. Fatal Thrombus Within a Drug-Eluting Stent Located O
(A) Postmortem X-ray of overlapping stents. (B) Cross section show
intracoronary thrombus. (C) Close up of area shown in (B). Struts at
tima, whereas struts at 6 o’clock, which appose the lipid core, are e
Table 2. Four Deﬁnitions of Vulnerable Plaque
Source (Ref. #)
Studies of triggering of onset of coronary
events (32)
A plaque prone to d
triggering event.
Angiographic studies (33,34) As above, but the p
baseline
Autopsy studies after coronary events (35,36) An inﬂamed TCFA
The PROSPECT study, a post-ACS and PCI
natural history study (37)
A plaque likely to ca
cardiac death, MI,
anginaACS  acute coronary syndrome; MI  myocardial infarction; PCI  percutaneoustandard care or treatment with a self-expanding
tent designed for non–flow-limiting plaques sus-
ected to be vulnerable (46).
Future improvements in IVUS technology include
he possibility that higher frequency imaging will lead
o improved spatial resolution and improved detection
f lumen and external elastic membrane borders.
ptical methods. INTRACORONARY ANGIOSCOPY. In
995, Uchida et al. (47) reported the first study linking
laque composition to patient outcome. Patients with
listening yellow plaques, presumably lipid-core
laques, had an increased incidence of future events.
ater Ohtani et al. (48) linked the number of yellow
laques to the risk of future events, thereby detecting
ulnerable patients. In 2009, Uchida (49) introduced
uorescence angioscopy for molecular imaging. Using
a Lipid-Core Plaque
stent struts, a lipid-core plaque with cholesterol crystals, and an
o’clock, which appose normal tissue, are well covered by neoin-
sed (14).
eﬁnition Feature
ption and thrombosis after a A functional deﬁnition independen
e need not be stenotic at This type of vulnerable plaque cou
by ischemia testing
A suspected vulnerable plaque and
imaging
a new coronary event including
table angina, and progressive
A broader deﬁnition of vulnerable
require disruption and thrombo
angina is an end pointver
ing
12D
isru t of histologic type
laqu ld not be detected
a good target for
use
uns
plaque that does not
sis because increasedcoronary intervention; TCFA  thin cap ﬁbroatheroma.
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886olorimetric angioscopic yellow as a gold standard,
amamoto et al. (50) found that the sensitivity,
pecificity, and accuracy of VH-IVUS for TCFA were
8%, 81%, and 75%, respectively.
CT and fourier domain OCT. OCT provides high-
esolution (10 m) images of arteries (51). Second-
eneration Fourier-domain OCT permits perfor-
ance of OCT, which requires removal of blood
rom the field of view, with only a single flush (52).
sing Fourier-domain OCT, Tearney et al. (1)
ere able to obtain microscopic images of the
oronary wall including identification of macro-
hages in a cap covering a lipid pool. Kataiwa et al.
53) found that the new nonocclusive method is safe
nd provides image quality equal to that obtained
ith the balloon occlusion method.
0
0 1
5
15
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20
25
Tim
All
Culprit lesion (CL) related
Non culprit lesion (NCL) related
Indeterminate
M
A
CE
 (%
)
Figure 4. MACE During Follow-up in the PROSPECT Study
During 3 years post-stenting for acute coronary syndrome, 20.4% o
mately half of the subsequent events came from the stented site, w
neous coronary intervention. Adapted from TCT Daily Staff (37).
Table 3. Histologic Features of Suspected Vulnerable Plaques
Type
Inﬂamed thin-cap ﬁbroatheroma, most frequent type and
present in 60% to 70% of ACS cases
Erosion site, present in 20% to 30% of events, more frequent
in women and younger patients with ACS
Calciﬁed nodule, present in 3% of patients with ACS
Plaque with a mural thrombus not producing a signiﬁcant
stenosisAbbreviation as in Table 2.Fujii et al. (54) found that OCT TCFAs were
ore frequent at the culprit site than at remote sites
n MI patients and that MI patients were more
ikely than stable patients to have multiple TCFAs.
Xu et al. (55) demonstrated that a combination of
ackscattering and attenuation coefficient measure-
ents could be used to improve tissue characteriza-
ion by OCT. Additional future improvements
nclude improved depth of penetration, which is
urrently limited to approximately 2 mm.
ultimodality imaging. OCT AND VH-IVUS. Sawada
t al. (2) interrogated plaques with both VH-IVUS
nd OCT to identify compositional and structural
eatures. Of the 126 plaques examined, 61 showed
CFAs by VH-IVUS and 36 were classified as
2 3
 Years
2.7%
11.6%
12.9%
20.4%
tients experienced a major adverse cardiac event (MACE). Approxi-
the other half coming from sites not treated at the initial percuta-
Features
Necrotic core (lipid core)
Thin cap 65 m
Inﬂammation
Increased vasa vasorum
Expansive remodeling
Increased plaque burden
Intraplaque hemorrhage
Spotty calciﬁcation
Luminal narrowing
Increased proteoglycans
Extensive calciﬁcation protruding into lumen
Considered to be a site of subsequent thrombosis because many
plaques causing events show repeated episodes of disruption
and thrombosise in
f pa
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887CFAs by OCT. In the combined analysis, 28
ere diagnosed as TCFAs by both methods. Dur-
ng follow-up, 3 of these sites, which did not have
flow-limiting stenosis at the initial study, demon-
trated stenosis progression requiring PCI (Fig. 1).
he authors conclude that the combined use of
CT and VH-IVUS, preferably in a single cathe-
er, might be a feasible approach for detecting
CFA.
Gonzalo et al. (56) also used both OCT and
H-IVUS to determine the frequency and distri-
ution of high-risk plaques at bifurcations. This
ual examination demonstrated that the proximal
im of the side branch ostium was the more likely
egion to contain a thin fibrous cap and a larger
ecrotic core.
VUS, OCT, AND ANGIOSCOPY. Kubo et al. (57) used
methods—angioscopy, IVUS, and OCT—in pa-
ients with AMI. Intracoronary thrombus at the
ulprit site was observed in all cases by OCT and
ngioscopy, whereas IVUS identified thrombus in
nly 33% of cases. The incidence of plaque rupture
as by 73% with OCT, 47% with angioscopy, and
0% with IVUS.
iffuse reﬂectance NIR spectroscopy. A catheter-
ased NIR spectroscopy system has been developed
o identify lipid-core plaque in coronary arteries
58). An NIR scan is performed through blood in a
anner similar to that used for IVUS and is
isplayed as a map of the artery called a chemogram
59). The system, which was validated by compar-
son of NIR chemograms with histologic results in
uman coronary autopsy specimens and with a
Figure 5. OCT and Angioscopic Images in a Patient
Optical coherence tomography (OCT) images (upper panel) and an
by angioscopy is diagnosed as a ﬁbrous plaque (*) by OCT. (B and
under a relatively thick (130 m) ﬁbrous cap. (C and upper panel)
lipid core (*) with a thin (20 m) ﬁbrous cap (arrow). The arc of lip
panel) Angioscopy shows a red thrombus over a yellow plaque. OC
thin cap (*). Reprinted, with permission, from Takano et al. (64). GW linical study (59,60), has now been used in 700
atients. Although the chemogram provides accu-
ate information about the presence of lipid-core
laque, it does not provide a structural image.
aman spectroscopy. Raman spectroscopy is simi-
ar to diffuse reflectance NIR spectroscopy, but it
elies on a more specific yet weaker signal created by
hotons that undergo a Raman shift within the
issue interrogated. A catheter-based system has
btained useful Raman signals from inside a human
oronary autopsy specimen implanted in a living
wine, but there are at present no reports of the use
f the system in patients (61).
agnetic resonance imaging. A catheter that con-
ained both the device to generate the magnetic
eld and the coil to send and receive radiofrequency
ignals was able to identify lipid-core plaque in
atients (62). However, the large size of the cath-
ter and long processing time limited its clinical
tility, and the system is no longer manufactured
or this use.
ntravascular thermography. There have been at-
empts to identify necrotic-core plaque by measur-
ng intracoronary temperature elevations. It was
ound, however, that the small thermal gradients
ssociated with inflamed plaques are difficult to
easure in flowing blood. A review of thermogra-
hy was recently published (63).
EASUREMENT OF CAP THICKNESS. The observa-
ion of thin caps in plaques that have ruptured has
ed to attempts to measure cap thickness in vivo.
ap thickness has been estimated by VH-IVUS,
ut the 100-m limit of resolution of IVUS does
copic images (lower panel). (A and upper panel) A white plaque
er panel) A white plaque by angioscopy contains a lipid core (*)
rk yellow plaque by angioscopy is shown by OCT to contain a
indicated by the angle between the 2 white lines. (D and upper
ows a protruding thrombus (arrow) overlying a lipid core with agios
upp
A da
id is
T shguidewire; other abbreviation as in Figure 1.
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888ot permit exact measurement of the thin cap of
nterest. OCT and angioscopy, however, have
reater resolution and have been used for more
irect measurements of cap thickness. Takano et al.
64) found the expected inverse relationship be-
ween the intensity of yellow coloring (assessed by
ngioscopy) of the plaque and cap thickness as
easured by OCT (Fig. 5). Plaques with the
ighest yellow color grade were found to have a cap
hickness of only 40  14 m.
dentification of Other Plaque Morphologies Associated
ithCoronaryEvents
lthough the effort to identify TCFAs has received
he greatest attention in the quest for identification
f vulnerable plaques, pathologic studies indicate
hat as many as 30% of clinical events occur at
rosion sites and a much smaller number occur at
he site of calcified nodules (Table 3).
Figure 6. Effect of Statin Therapy on Cap Thickness
Angiographic (A and E), intravascular ultrasound (B and F), and OC
OCT shows an increase in cap thickness (D, H, arrows) from 110 m
Table 4. Comparison of Intracoronary Imaging Modalities
IVUS
(40 MHz)
Axial resolution, m 100
PCI (stent expansion and complications) 
Necrotic core 
Detection of thin cap 
Thrombus 
Stent tissue coverage 
Expansive remodeling 
Measurement through blood 
Adapted from Maehara et al. (41)
  excellent;   good;   possible;   impossible; IVUS  intravascin Tables 1 and 2.In vivo identification of erosion sites lags behind
he recent success in identifying necrotic cores.
atal thrombi over erosion sites are more likely to
e recurrent than thrombi over ruptured TCFAs
65). Although OCT may be able to identify some
rosion sites, imaging of sites prone to erosion will
equire more detailed assessment of local molecular
rocesses than is possible with current intracoronary
maging techniques (Fig. 6) (66).
olecular ImagingofCoronaryAtherosclerotic Plaques
full understanding of the status of coronary
therosclerosis in a patient will require information
bout the molecular and cellular processes within
laques (67,68). Fortunately, progress in molecular
nd cellular imaging indicates that invasive and
ven noninvasive techniques offer promise for iden-
ification of molecular processes in the coronary
laques of patients (69–71).
–H) images at baseline and after 9 months of statin therapy (66).
baseline (D) to 320 m at 9-month follow-up (H).
VH
MHz) OCT
Near-infrared
Spectroscopy Angioscopy
200 10 NA 10–50
   
   
   
   
   
   
   
ultrasound; NA  not available; VH  virtual histology; other abbreviations asT (C(20
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889Chang and Jaffer (71) injected an NIR fluores-
ence agent that is activated by proteases into
therosclerotic rabbits. Catheter interrogation of
he iliac arteries then demonstrated activation of the
gent, indicating the presence of protease activity in
laques. The agent colocalized with immunoreac-
ive macrophages and cathepsin B, thereby identi-
ying inflammation.
onclusions
ntracoronary imaging is an active research field
ith great potential to improve patient care. In the
ffort to detect vulnerable plaque, the most signif-
cant development is the continued accumulation of
vidence that certain plaques are more likely to
ause clinical events and therefore deserve the term
ulnerable; the evidence includes the early angio-
copic study by Uchida (47), the recent observation
hat 3 patients with TCFAs by both VH-IVUS and
CT measures experienced events (2), and the
nding in the PROSPECT study that certain sitesanalysis from the TAXUS IV, V, and grated backscatter iAs is apparent from Table 4, the various intra-
oronary imaging methods are complementary.
ence, extensive efforts are under way to build
ombined imaging devices. The improved charac-
erization of coronary plaques with these new tech-
iques has the potential to improve the selection of
herapy for patients, reduce the complications of
tenting, and identify vulnerable plaques so they
ay be treated before they cause an event. Multiple
linical studies are in progress to determine how
hese new diagnostic capabilities might be used to
mprove the daily care of patients with coronary
rtery disease.
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